$2.23 Billion in Sales Expected for Bausch Health Companies Inc. (NYSE:BHC) This Quarter

Equities analysts predict that Bausch Health Companies Inc. (NYSE:BHC) will announce $2.23 billion in sales for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for Bausch Health Companies’ earnings. The lowest sales estimate is $2.19 billion and the highest is $2.27 billion. Bausch Health Companies posted sales of $2.21 billion during the same quarter last year, which would indicate a positive year over year growth rate of 0.9%. The firm is scheduled to report its next quarterly earnings report on Wednesday, February 23rd.

According to Zacks, analysts expect that Bausch Health Companies will report full year sales of $8.47 billion for the current year, with estimates ranging from $8.43 billion to $8.57 billion. For the next financial year, analysts anticipate that the company will post sales of $8.91 billion, with estimates ranging from $8.71 billion to $9.20 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that follow Bausch Health Companies.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Tuesday, November 2nd. The company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.07. Bausch Health Companies had a negative return on equity of 2,440.75% and a negative net margin of 13.85%. The business had revenue of $2.11 billion for the quarter, compared to analysts’ expectations of $2.15 billion.

A number of equities research analysts have recently commented on BHC shares. Barclays lowered their target price on Bausch Health Companies from $35.00 to $31.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 4th. BMO Capital Markets reissued a “hold” rating on shares of Bausch Health Companies in a report on Monday, November 8th. Jefferies Financial Group reissued a “buy” rating on shares of Bausch Health Companies in a report on Friday, October 1st. Finally, Royal Bank of Canada decreased their price objective on Bausch Health Companies from $41.00 to $40.00 and set an “outperform” rating for the company in a report on Wednesday, November 3rd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $36.22.

Shares of NYSE BHC traded up $0.08 during mid-day trading on Friday, reaching $26.11. 1,280,183 shares of the company’s stock were exchanged, compared to its average volume of 3,088,960. The firm has a market capitalization of $9.37 billion, a price-to-earnings ratio of -7.96, a price-to-earnings-growth ratio of 1.45 and a beta of 1.56. Bausch Health Companies has a 52 week low of $18.49 and a 52 week high of $34.80. The firm has a 50-day moving average price of $27.66 and a two-hundred day moving average price of $28.69.

A number of hedge funds have recently made changes to their positions in BHC. Vanguard Group Inc. increased its stake in shares of Bausch Health Companies by 1.1% during the second quarter. Vanguard Group Inc. now owns 9,307,234 shares of the company’s stock valued at $272,887,000 after buying an additional 96,748 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Bausch Health Companies by 48.2% in the second quarter. Price T Rowe Associates Inc. MD now owns 7,850,573 shares of the company’s stock worth $230,179,000 after purchasing an additional 2,553,297 shares during the period. Laurion Capital Management LP grew its stake in Bausch Health Companies by 10.9% in the third quarter. Laurion Capital Management LP now owns 7,536,780 shares of the company’s stock worth $209,899,000 after purchasing an additional 741,378 shares during the period. Guardian Capital LP grew its stake in Bausch Health Companies by 13.7% in the second quarter. Guardian Capital LP now owns 4,907,407 shares of the company’s stock worth $144,175,000 after purchasing an additional 591,054 shares during the period. Finally, Miller Value Partners LLC grew its stake in Bausch Health Companies by 2.5% in the second quarter. Miller Value Partners LLC now owns 3,330,390 shares of the company’s stock worth $97,647,000 after purchasing an additional 79,969 shares during the period. Hedge funds and other institutional investors own 75.43% of the company’s stock.

About Bausch Health Companies

Bausch Health Cos., Inc engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products.

Recommended Story: What is the cash asset ratio?

Get a free copy of the Zacks research report on Bausch Health Companies (BHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.